Completed PHASE3 NCT00054717

Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)

Randomized, Open-label, Comparative Safety and Efficacy Study of Tipranavir Boosted With Low-dose Ritonavir (TPV/RTV) Verses Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-experienced Patients.

Sponsor: Boehringer Ingelheim

Conditions HIV Infections

Interventions Comparator Protease Inhibitor (CPI) Ritonavir(r) Tipranavir

Updated 6 times since 2017 Last updated: Jun 23, 2014 Started: Jan 31, 2003 Primary completion: Sep 30, 2008

This PHASE3 trial investigates HIV Infections and is currently completed. Boehringer Ingelheim leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boehringer Ingelheim

Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Albany, United States , Ann Arbor, United States , Annandale, United States , Atlanta, United States , Baltimore, United States , Berkeley, United States , Bethesda, United States , Beverly Hills, United States , Boise, United States and 73 more locations